Transmission roles of symptomatic and asymptomatic COVID-19 cases: a modeling study

Authors:

Jianbin Tan^{1†}, Yang Ge^{2†}, Leonardo Martinez³, Jimin Sun⁴, Changwei Li⁵, Adrianna Westbrook², Enfu Chen⁴, Jinren Pan⁴, Yang Li⁶, Feng Ling⁴, Zhiping Chen^{4‡}, Hui Huang^{1‡}, Ye Shen^{2‡}.

Author affiliations:

1 Sun Yat-Sen University, School of Mathematics, Guangzhou, China;

2 University of Georgia, College of Public Health, Department of Epidemiology and Biostatistics, Athens, Georgia, United States;

3 Boston University, Department of Epidemiology, Boston, United States;

4 Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China;

5 Tulane University School of Public Health and Tropical Medicine, Department of Epidemiology, New Orleans, Louisiana, United States;

6 Renmin University of China, School of Statistics, Beijing, China.

† Joint first authors; ‡ Joint corresponding Author.

1 **Key Points**

2 Question:

3 What is the transmissibility of COVID-19 asymptomatic and symptomatic cases, respectively?

4 To date, they have not been well quantified in existing literature.

5

6 Findings:

7 The transmissibility of asymptomatic and symptomatic COVID-19 increases with patient age.

8 The asymptomatic cases had a 66.72% lower transmissibility rate than symptomatic cases.

9

10 Meaning:

11 The transmissibility of asymptomatic COVID-19 cases is not low. Asymptomatic cases are

12 harder to detect compared to symptomatic cases. Consequently, the burden of asymptomatic

13 transmission could potentially dominate the spreading in certain scenarios.

Background

COVID-19, caused by the novel coronavirus (SARS-CoV-2),[1] is a great threat to human health.[2] Nonpharmaceutical interventions such as social distancing, case isolation and contact quarantines are the most common tools for suppressing the pandemic in many countries where vaccine supplements are limited.[3–5] However, much remains unclear regarding SARS-CoV-2 transmissibility which undermined the efforts for tailored interventions.[6,7] COVID-19 patients may present and remain pre-symptomatic, asymptomatic, or symptomatic and transmission may occur at each of these disease states.[8–10] Unlike the transmission caused by symptomatic cases, pre-symptomatic and asymptomatic transmission are hard to detect and difficult to measure as many surveillance systems rely on symptom-based population screening.[8,11–13] Previous case studies suggested that asymptomatic COVID-19 individuals are less infectious than symptomatic cases.[14,15] However, asymptomatic cases may spread for a longer period due to reduced efficiency in case detection.[16] Several studies investigated the silent transmission of SARS-CoV-2, but presented contradictory conclusions with estimated burden ranged from 3% to 79%.[16–18]

Without sufficient follow-up time, asymptomatic and pre-symptomatic cases are often indistinguishable. Consequently, studies using population-level data to estimate of age-specific transmission and susceptibility parameters commonly falls short of accuracy which potentially explains for the heterogeneous findings from different studies.[19–21] Common issues were modeling without data on observed asymptomatic infection[16–18,22] and inclusion of pre-symptomatic cases as part of an asymptomatic classification,[19–21] . Meanwhile, few studies assessing asymptomatic infectiousness and viral load with limited sample sizes fail to capture the transmission dynamics.[14,15,23–30] No studies to date have attempted to combine reliable case symptom classification with age-dependent transmissibility, social contact measures, and susceptibility parameters at the population level to learn the transmission dynamics. However, a comprehensive understanding of the age-specific symptomatic and asymptomatic transmission dynamics at the population level is essential to the evaluation of an epidemic and the creation of responding health policies.

45 In this study, we report on a longitudinal cohort of all diagnosed COVID-19 infections, between
46 January 8th and February 23rd, 2020, from Zhejiang province, China. All patients without initial
47 symptoms were followed by at least 90 days to distinguish between asymptomatic and
48 pre-symptomatic cases, an essential procedure rarely implemented by previous studies to ensure
49 reliable classification of case symptoms. We then built age-stratified compartmental models to
50 study the age-dependent population-level transmission roles of symptomatic and asymptomatic
51 COVID-19 cases.

Methods

Data sources

Zhejiang province is an eastern coastal province adjacent to Shanghai city with a population of approximately 54 million individuals.[31] The first and only major wave of the COVID-19 epidemic in Zhejiang began on early January, 2020 and continued until late February, 2020 after which only sporadic single-case events were observed. We included information from all confirmed cases in this major wave (a total of 1342 cases), as well as a follow-up investigation related to all detected asymptomatic infections to distinguish between asymptomatic and pre-symptomatic cases. Individual-level data related to the symptom onset of symptomatic infections, as well as COVID-19 confirmation dates and ages of both symptomatic and asymptomatic cases were collected. On January 23rd, 2020, the provincial government changed its infectious disease alert category to the highest level and, on February 1st, began a comprehensive set of interventions.[32] As of April 10th, 2020, the date in which we restricted our data for this analysis, no additional outbreak had been observed. Trained health professionals investigated each confirmed case with a predefined questionnaire by which basic health and demographic information were collected.

Definition of symptomatic and asymptomatic cases

All confirmed cases and their close contacts were isolated or quarantined after being identified through contact tracing. During the isolation/quarantine period, cases and their contacts received regular testing and daily symptom screening for fever, cough, and shortness of breath. Tests for case confirmation were conducted using reverse transcription polymerase chain reaction (RT-PCR) or viral genome sequencing on samples from throat swabs (oropharynx and nasopharynx). If a case or contact had a positive test result but without any symptoms, they would be temporarily classified as an asymptomatic/pre-symptomatic case at the time. All cases were followed for at least 90 days after their initial positive test to distinguish between asymptomatic and pre-symptomatic cases. Among these subjects, those who developed symptoms later would receive a final classification as a symptomatic case. Others who had never developed any symptoms between their initial positive test and first subsequent negative PCR test would be classified as asymptomatic cases.

Model structure

We divided the total population of Zhejiang province into seven age groups (Figure 1). To consider transmission related to symptomatic and asymptomatic infections among different age groups, our model contained 8 compartments for the i^{th} age group: susceptible population (S^i), exposed contacts (E^i), pre-symptomatic cases (I_{ps}^i , infected but have not yet developed symptoms), symptomatic cases (I_s^i), asymptomatic cases (I_a^i , infected but asymptomatic till confirmed/recovery), and removed/recovery groups (R_{cs}^i , R_{ca}^i , R_h^i). We assumed new infections were driven by transmission from compartments of I_{ps}^i , I_s^i and I_a^i in all age groups.

Asymptomatic cases (I_a^i) were infections without typical symptoms which were often untraceable in the clinical survey and, therefore, their contribution to population-level transmission would be underestimated. To account for this, we assumed only a proportion of asymptomatic infections were detected (R_{ca}^i), while others (R_h^i) would be unconfirmed. We were able to observe disease confirmation date but not the date of infection for the period from cases becoming infectious to the diagnosis of COVID-19 ($\mathcal{A}_1^i$) in those with confirmed asymptomatic infection. Based on the virus shedding pattern of asymptomatic infections reported in previous studies,[13,15,33,34] we assumed that this period should be less than 30 days, after which virus shedding generally ceases, and infection is no longer detectable through pathogen-specific testing.

To identify age-varying transmissibility and susceptibility,[22] we assumed a time-varying curve for the average contact numbers of i^{th} age group with j^{th} age group (c_t^{ij}), which is estimated with the contact matrix between age groups through surveys conducted in Shanghai.[35,36] We separate the probability of infection into two components: transmissibility (T) and susceptibility (s). We define transmissibility (T) as the infectiousness of one case. Similarly, we define susceptibility (s) as the probability of acquiring infection from an infectious case ($T = 1$). Therefore, $s = 0$ corresponds to a situation in which the susceptible individuals are immune to the disease. We assumed that case transmissibility would depend on age and the presence of symptoms. To capture the age-dependent pattern, B splines basis functions were

used to model the variability in age-varying transmissibility smoothly. Finally, the compartmental model was fitted to the daily new symptomatic and asymptomatic cases in Zhejiang province for each age group with Markov Chain Monte Carlo (MCMC) algorithm.

All analyses were implemented in R version 3.5.1. Packages of deSolve,[37] extraDistr,[38] and splines[39] were used for model fitting. Unless stated otherwise, the medians of the posterior distributions were used as the point estimators of parameters and simulated numbers.

Ethics approval

The research protocol was approved by the institutional review board at the Zhejiang Provincial Center for Disease Control and Prevention. The study was based on deidentified data.

Results

Transmissibility

The estimated transmissibility presented an age-dependent difference between symptomatic and asymptomatic infections (Figure 2). While the transmission of symptomatic cases monotonically increased with increasing age, the transmissibility of asymptomatic infection remained low until age 40, after which point it significantly increased with increasing age. The age-varying ratios of the two kinds of transmissibility indicated asymptomatic cases were, on average, 66.72% lower in transmission than symptomatic cases. However, the difference between the two types of infections was not as big in those aged 0-20 and 60+ years old, but became more obvious in the middle-aged group where the ratios were as low as 24.42% and 23.38% for those aged 30-40 and 40-50 years old, respectively.

The proportion of asymptomatic cases

In Figure 3, the proportion of asymptomatic cases ($\frac{R_h^i + R_{ca}^i}{R_h^i + R_{cs}^i + R_{ca}^i}$) estimated by our model was much larger than what was observed in the data. The average proportion of asymptomatic cases was 28.22% (95%CI: 22.97% - 34.56%) of the total counts of cases in our model estimation, but was 9.24% in the observed data ($\frac{R_{ca}^i}{R_{cs}^i + R_{ca}^i}$). In our estimation from the empirical data, the highest proportion of asymptomatic case was among 0-10 (60.18% (95%CI: 53.61% - 66.99%)) and 10-20 (57.64% (95%CI: 47.45% - 66.98%)) years old groups. For asymptomatic cases, we further estimated the proportion of cases that failed to be detected ($\frac{R_h^i}{R_h^i + R_{ca}^i}$). In the posterior samples, the average proportion of unconfirmed cases in all asymptomatic infections was 74.10% (95%CI: 65.85% - 80.72%). The maximum proportion of unconfirmed cases was observed in 20-30 years old at 86.59% (95%CI: 73.64% - 92.19%).

Symptomatic and asymptomatic transmission

To explore the impact of symptomatic and asymptomatic transmission, we present several features of the estimated dynamic of the epidemic and the transmission burden caused by symptomatic and asymptomatic cases in Figure 4. The estimated number of daily new

transmissions reached a peak around ten days prior to the peak of the daily reported new confirmed cases (Figure 4A). We estimated a substantial number of undetected asymptomatic cases (109 (95%CI: 73 - 164)) were infected before the first asymptomatic case was diagnosed (January 27th) (Figure 4B). New transmissions were nearly eliminated by February 2nd, 2020 (Figure 4A), when a comprehensive set of restrictions had been implemented. The peak of the two types of transmission both occurred between January 18th to 22nd (Figure 4C). The average burden of asymptomatic transmission during the major outbreak period was estimated to be 12.86% (95%CI: 7.54% - 19.27%). The burden of asymptomatic transmission increased with time, ranging from 7.77% to 16.03% (Figure 4D). Simulation studies were conducted to investigate the dynamic changes in the transmission burden over time during a prolonged epidemic. When the duration of the decreasing process of the contact function (represented by “*m*”) was prolonged by two weeks and each individual’s daily contact number was increased by one person during the outbreak period, we found a slower decreasing trend in daily new cases infected by asymptomatic cases compared with that contributed by symptomatic cases. Additional scenarios were generated demonstrating the possibility of asymptomatic transmission dominating the total transmission under different conditions, especially when the duration between symptom onset and disease confirmation for symptomatic infections was shortened and the asymptomatic infections were not controlled.

Age-depended transmission

Within each age group, we observed heterogeneous transmission contributions during different time periods (Figure 5A). Early on in the epidemic, the transmission burden was dominated by persons of 50-60 years old (32.75% from January 8th to January 12th), but the proportion of transmission contribution from people over 60 years old significantly increased over time, surpassing the 50-60 years old and reaching 30.42% by February 1st, 2020. The proportion of transmission contribution among varying age groups was distinct between symptomatic and asymptomatic cases (Figure 5B). The majority of both symptomatic and asymptomatic transmissions were contributed by persons over 30 years old (Table S9). Individuals below 30 years old only contributed less than 5% of all symptomatic transmission and approximately 12% of all asymptomatic transmission, respectively, despite representing almost 40% of the entire population. Contributions to asymptomatic transmission among 20-30 and >60 year age groups

185 (9.44%, and 31.73%, respectively) were substantially higher than their corresponding
186 contributions to symptomatic transmission (3.77%, and 26.55%, respectively). To further
187 understand possible age-dependent vaccination strategies, a simulation of seven scenarios was
188 conducted to assess the percentage decline in different age groups if one age group were to
189 achieve 100% immunity by vaccinations. The results suggested that vaccinations targeting age
190 groups above 30 years are likely to be more effective at the population level, with the most
191 percentage decline of cases from the entire population achieved by targeting the 50-60 years old
192 group. Meanwhile, vaccinating those younger than 30 years old are more likely to benefit their
193 own age groups.

Discussion

In our study, we found that asymptomatic cases were over 60% less infectious compared to symptomatic cases. While great efforts like mass screening and strict contact tracing were conducted, our results suggested that a large proportion of asymptomatic infections were still not detected.[40] The burden of asymptomatic transmission was inferior in the early outbreak but could become higher with the continuous spread of COVID-19. Under strained resources, age-specific prevention and control strategies aimed at the middle age population may return greater population-level benefits.

Current evidence suggests that asymptomatic COVID-19 cases are generally less infectious[14] than cases with symptoms. We found that this difference may partially be explained by patient age. Age may directly impact COVID-19 transmission through virus shedding patterns[15] as discussed in previous studies.[41] Symptoms are commonly mild in children[42] but severe in the elderly.[43] While still debatable,[44] higher severity has been associated with increased shedding of the virus.[45] In our study, symptomatic and asymptomatic cases were most infectious in individuals 60 years old or older. In contrary to the monotonic increasing association between age and transmission in symptomatic cases, there was a plateau of a low degree of transmission in young asymptomatic infections. We suspect older adults are not only the most vulnerable to succumb to COVID-19 but also may be more likely to transmit once infected, regardless of symptom status. Interventions attempting to suppress asymptomatic transmission, such as mask-wearing, should primarily focus on older adults if interventions to the whole community are not feasible.

Similar to previous studies, our results suggest a small proportion of asymptomatic cases have been detected since the start of the COVID-19 pandemic in our setting.[46–48] Symptom-based screening has limited capability in asymptomatic case detection,[6] while mass pathogen or immunological-based testing at the population-level consumes tremendous health resources, and thus is not feasible in most settings. Considering these challenges, age-dependent screening strategies may be more practical. We found that the highest number of undetected asymptomatic cases was among young adults aged 20 to 30 years old (Table S7) and the corresponding

transmission contribution was significantly higher than that of symptomatic case (Figure 5B). Young people were less likely to adhere to social distancing guidelines,[49] often had mild symptoms or were asymptomatic after infection,[50] and were not prioritized in prevention and controlling strategies.[51] Meanwhile, younger asymptomatic patients were also more likely to have normal CAT scan findings, which may further complicate case detection.[12] Case detection of asymptomatic COVID-19 cases based on current control strategies implemented in this study is alarming.

Based on the estimated transmission contributions from symptomatic and asymptomatic infections, roughly 13% of infections were associated with asymptomatic transmission and that percentage continuously increased with a prolonged period. The overall burden of transmission was mainly contributed by symptomatic cases at the beginning of the epidemic, but asymptomatic infections appeared to have increasing percentages of subsequent cases later on. Additional simulations suggested that the transmission burden could even be dominated by asymptomatic transmissions under certain circumstances. Therefore, the spreading potential of asymptomatic cases cannot be ignored, especially in the later stages of the epidemic and in regions where social distancing has not been mandated. Meanwhile, potential differences in transmission burden by age groups, as shown in Figure 5 and S6, supports prioritizing age-dependent prevention and control strategies when facing strained resources. As the larger contributor to the transmission of COVID-19, the older age population is not only a highly vulnerable group but should also be the primary target for prevention strategies. Vaccine Strategies prioritizing the population between 30-60 years old are likely to have the most population-level benefits.

There are several limitations in this study. First, data collection likely missed potential cases of the epidemic, despite intensified efforts devoted by the local investigation team to trace contacts. Due to this, we introduced a compartment in our model (R_h^i) to adjust for poor case ascertainment and missing cases. Second, transmissibility and susceptibility were two factors related to symptomatic and asymptomatic transmission estimation and can be difficult to capture simultaneously. We used the susceptibility estimates from a previous study[22] as priors in our model to account for this parameter identification problem. Third, the contact survey data we

used in our model were obtained in Shanghai, a city adjacent to Zhejiang province. Although the two regions share a similar culture and modes of social activities, there were potential uncertainties associated with the discrepancies in contact matrices. To address this limitation, we introduced a correction parameter in our model, so these uncertainties were partially adjusted for in the analyses.

Conclusion

In summary, our results suggest individual-level transmissibility of COVID-19 increases with patient age, therefore targeting older age groups with prevention and intervention strategies is expected to be more efficient. While asymptomatic cases are difficult to trace, the burden of asymptomatic transmission is still sizable and should not be ignored. The results from our study can be used to inform policy decisions on pandemic control and safe reopening.

References

1. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. Massachusetts Medical Society; 2020;382:1708–20.
2. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard (12/12/2020) [Internet]. [cited 2020 Dec 12]. Available from: <https://covid19.who.int>
3. Ferguson N, Laydon D, Nedjati Gilani G, Imai N, Ainslie K, Baguelin M, et al. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand [Internet]. Imperial College London; 2020 Mar. Available from: <http://spiral.imperial.ac.uk/handle/10044/1/77482>
4. Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, et al. The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. *The Lancet Public Health*. Elsevier; 2020;5:e261–70.
5. Lewnard JA, Lo NC. Scientific and ethical basis for social-distancing interventions against COVID-19. *The Lancet Infectious Diseases*. 2020;20:631–3.
6. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control Covid-19. *N Engl J Med*. 2020;382:2158–60.
7. Huff HV, Singh A. Asymptomatic Transmission During the Coronavirus Disease 2019 Pandemic and Implications for Public Health Strategies. *Clinical Infectious Diseases*. 2020;71:2752–6.
8. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *N Engl J Med*. Massachusetts Medical Society; 2020;382:970–1.
9. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med*. 2020;382:929–36.
10. Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, et al. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. *N Engl J Med*. 2020;382:1278–80.
11. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020;581:465–9.
12. Kronbichler A, Kresse D, Yoon S, Lee KH, Effenberger M, Shin JI. Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis. *International Journal of Infectious Diseases*. 2020;98:180–6.
13. Han MS, Seong M-W, Kim N, Shin S, Cho SI, Park H, et al. Viral RNA Load in Mildly Symptomatic and Asymptomatic Children with COVID-19, Seoul, South Korea. *Emerging Infectious Diseases*. 2020;26:2497–9.

14. Gao M, Yang L, Chen X, Deng Y, Yang S, Xu H, et al. A study on infectivity of asymptomatic SARS-CoV-2 carriers. *Respir Med.* 2020;169:106026.
15. Kim SE, Jeong HS, Yu Y, Shin SU, Kim S, Oh TH, et al. Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients. *Int J Infect Dis.* 2020;95:441–3.
16. Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, et al. The implications of silent transmission for the control of COVID-19 outbreaks. *PNAS. National Academy of Sciences;* 2020;117:17513–5.
17. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science.* 2020;368:489–93.
18. Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dörner L, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. *Science* [Internet]. American Association for the Advancement of Science; 2020 [cited 2020 Dec 21];368. Available from: <https://science.sciencemag.org/content/368/6491/eabb6936>
19. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci China Life Sci. Nature Publishing Group;* 2020;63:706–11.
20. Huang L, Zhang X, Zhang X, Wei Z, Zhang L, Xu J, et al. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: A prospective contact-tracing study. *J Infect.* 2020;80:e1–13.
21. Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, et al. CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. *J Infect.* 2020;81:e33–9.
22. Davies NG, Klepac P, Liu Y, Prem K, Jit M, CMMID COVID-19 working group, et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. *Nat Med. Nature Publishing Group;* 2020;26:1205–11.
23. Zhou R, Li F, Chen F, Liu H, Zheng J, Lei C, et al. Viral dynamics in asymptomatic patients with COVID-19. *International Journal of Infectious Diseases.* 2020;96:288–90.
24. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. *N Engl J Med. Massachusetts Medical Society;* 2020;
25. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis.* 2020;20:669–77.

- 339 26. CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus
340 Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal
341 Wkly Rep. 2020;69:343–6.
- 342 27. Kong D, Zheng Y, Wu H, Pan H, Wagner AL, Zheng Y, et al. Pre-symptomatic transmission
343 of novel coronavirus in community settings. Influenza Other Respir Viruses. 2020;14:610–4.
- 344 28. Furukawa NW, Brooks JT, Sobel J. Evidence Supporting Transmission of Severe Acute
345 Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic. Emerg Infect
346 Dis [Internet]. 2020 [cited 2020 Aug 8];26. Available from:
347 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323549/>
- 348 29. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of
349 coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship,
350 Yokohama, Japan, 2020. Eurosurveillance [Internet]. 2020 [cited 2020 Apr 5];25. Available
351 from: <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.10.2000180>
- 352 30. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed Asymptomatic Carrier
353 Transmission of COVID-19. JAMA. American Medical Association; 2020;323:1406–7.
- 354 31. Bureau of Statistics. Zhejiang Provincial Bureau of Statistics: Sixth Census Data [Internet].
355 2014 [cited 2020 Jul 30]. Available from:
356 http://tjj.zj.gov.cn/art/2014/9/3/art_1530851_20980968.html
- 357 32. Chong KC, Cheng W, Zhao S, Ling F, Mohammad KN, Wang MH, et al. Monitoring disease
358 transmissibility of 2019 novel coronavirus disease in Zhejiang, China. International Journal of
359 Infectious Diseases. 2020;96:128–30.
- 360 33. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and immunological
361 assessment of asymptomatic SARS-CoV-2 infections. Nat Med. Nature Publishing Group;
362 2020;26:1200–4.
- 363 34. Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, et al. Clinical Course and Molecular Viral
364 Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a
365 Community Treatment Center in the Republic of Korea. JAMA Internal Medicine.
366 2020;180:1447–52.
- 367 35. Zhang J, Litvinova M, Liang Y, Wang Y, Wang W, Zhao S, et al. Changes in contact
368 patterns shape the dynamics of the COVID-19 outbreak in China. Science. 2020;368:1481–6.
- 369 36. Zhang J, Klepac P, Read JM, Rosello A, Wang X, Lai S, et al. Patterns of human social
370 contact and contact with animals in Shanghai, China. Scientific Reports. Nature Publishing
371 Group; 2019;9:15141.
- 372 37. Soetaert K, Petzoldt T, Setzer RW. Solving Differential Equations in R: Package deSolve.
373 Journal of Statistical Software. 2010;33:1–25.
- 374 38. Wolodzko T, Wolodzko MT. Package ‘extraDistr.’ 2017;

39. Perperoglou A, Sauerbrei W, Abrahamowicz M, Schmid M. A review of spline function procedures in R. *BMC Medical Research Methodology*. 2019;19:46.
40. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature*. Nature Publishing Group; 2020;584:257–61.
41. Esposito S, Principi N. To mask or not to mask children to overcome COVID-19. *Eur J Pediatr*. 2020;179:1267–70.
42. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among Children in China. *Pediatrics*. American Academy of Pediatrics; 2020;145:e20200702.
43. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*. 2020;395:1054–62.
44. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature Medicine*. Nature Publishing Group; 2020;26:672–5.
45. Liu Y, Yan L-M, Wan L, Xiang T-X, Le A, Liu J-M, et al. Viral dynamics in mild and severe cases of COVID-19. *The Lancet Infectious Diseases*. 2020;20:656–7.
46. Fauci AS, Lane HC, Redfield RR. Covid-19 — Navigating the Uncharted. *New England Journal of Medicine*. 2020;382:1268–9.
47. García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. *Front Immunol*. 2020;11:1441.
48. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection□: A Narrative Review. *Ann Intern Med*. 2020;173:362–7.
49. Czeisler MÉ, Tynan MA, Howard ME, Honeycutt S, Fulmer EB, Kidder DP, et al. Public attitudes, behaviors, and beliefs related to COVID-19, stay-at-home orders, nonessential business closures, and public health guidance—United States, New York City, and Los Angeles, May 5–12, 2020. *Morbidity and Mortality Weekly Report*. Centers for Disease Control and Prevention; 2020;69:751.
50. Felsenstein S, Hedrich CM. COVID-19 in children and young people. *The Lancet Rheumatology*. Elsevier; 2020;2:e514–6.
51. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. COVID-19: Towards controlling of a pandemic. *The Lancet*. 2020;395:1015–8.

Figures

Figure 1. Compartmental model for SARS-CoV-2 transmission, where “j” represents another age group different from “i” for the compartments.

Figure 2. (A) The estimated transmissibility and 95% credible intervals for each age group; (B) The ratios of asymptomatic transmissibility to symptomatic transmissibility for seven age groups.

Figure 3. The proportion of asymptomatic infections and unconfirmed asymptomatic infections until February 22nd, 2020 for seven age groups.

Figure 4. The estimated dynamics of the epidemic and the transmission burdens from symptomatic and asymptomatic cases. (A): The estimated numbers of daily new transmissions with 95% credible intervals and the observed numbers of daily reported new confirmed cases from January 8th to February 22nd, 2020; (B) The observed numbers of daily reported new confirmed symptomatic (R_{cs}) and asymptomatic cases (R_{ca}) and the estimated numbers of daily new cases that failed to be detected (R_h) with 95% credible intervals; (C): The estimated numbers of infected individuals caused by symptomatic and asymptomatic transmission over time, with 95% credible intervals; (D): Corresponding proportions of symptomatic and asymptomatic transmissions over different time periods.

Figure 5. The burden of transmission caused by different ages. (A) The estimated (contribution) ratios of new transmissions from different ages over different time periods; (B) The estimated (contribution) ratios of symptomatic and asymptomatic transmission from different ages. The contribution ratio of each age group is calculated by the proportion of the transmissions caused by the corresponding age group to the number of all transmissions in each transmission type, from January 8th to February 1st, 2020.

Figure 1. Compartmental model for SARS-CoV-2 transmission, where “j” represents another age group different from “i” for the compartments.

437 Figure 2. (A) The estimated transmissibility and 95% credible intervals for each age group; (B)
 438 The ratios of asymptomatic transmissibility to symptomatic transmissibility for seven age
 439 groups.

Figure 3. The proportion of asymptomatic infections and unconfirmed asymptomatic infections until February 22nd, 2020, for seven age groups. The estimated proportions of asymptomatic cases, the proportions of cases that failed to be detected among asymptomatic infections (unconfirmed proportions), and the observed proportions of asymptomatic cases are defined as: $\frac{R_h^i + R_{ca}^i}{R_h^i + R_{cs}^i + R_{ca}^i}$, $\frac{R_h^i}{R_h^i + R_{ca}^i}$, and $\frac{R_{ca}^i}{R_{cs}^i + R_{ca}^i}$, respectively. The 95% credible intervals for the estimated proportions of asymptomatic cases are shown for each age group.

Figure 4. The estimated dynamics of the epidemic and the transmission burdens from symptomatic and asymptomatic cases. (A): The estimated numbers of daily new transmissions with 95% credible intervals and the observed numbers of daily reported new confirmed cases from January 8th to February 22nd, 2020; (B) The observed numbers of daily reported new confirmed symptomatic (R_{cs}) and asymptomatic cases (R_{ca}) and the estimated numbers of daily new cases that failed to be detected (R_h) with 95% credible intervals; (C): The estimated numbers of infected individuals caused by symptomatic and asymptomatic transmission over time, with 95% credible intervals; (D): Corresponding proportions of symptomatic and asymptomatic transmissions over different time periods.

Figure 5. The burden of transmission caused by different ages. (A) The estimated (contribution) ratios of new transmissions from different ages over different time periods; (B) The estimated (contribution) ratios of symptomatic and asymptomatic transmission from different ages. The contribution ratio of each age group is calculated by the proportion of the transmissions caused by the corresponding age group to the number of all transmissions in each transmission type, from January 8th to February 1st, 2020.

464